Findings from epidemiologic studies examining associations of serum retinol and carotenoids with prostate cancer risk have been inconsistent. This case-control study nested in the Prostate Cancer Prevention Trial evaluated associations of serum retinol and carotenoids with total, low- and high-grade prostate cancer risk in a highly-screened study population.
We used logistic regression adjusting for age, family history of prostate cancer, race, BMI and serum cholesterol to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer by quartiles of serum retinol and carotenoids, separately in the placebo (975 cases/1009 frequency-matched controls) and finasteride (708 cases/743 frequency-matched controls) arms of the trial.
Serum retinol concentrations were associated with increased risk of total prostate cancer [OR (95% CI) comparing the highest quartile of serum retinol to the lowest: 1.30 (1.00, 1.68)] and high-grade prostate cancer [OR (95% CI): 1.74 (1.14, 2.68)] in the placebo arm of the trial only. Also in the placebo arm, there was a moderate positive association of α-carotene with risk of total prostate cancer [OR (95% CI): 1.32 (1.01, 1.73)]. None of the other carotenoids was associated with prostate cancer risk in the placebo arm. No associations were observed for retinol and carotenoids in the finasteride arm.
In the placebo arm of this prospective study, high serum retinol and α-carotene concentrations were associated with increased risk of total and high-grade prostate cancers.
Men with higher levels of serum retinol and α-carotene may be at increased risk for prostate cancer.